Kirsten Bornemann-Kolatzki

Dr. Kirsten Bornemann-Kolatzki

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
ESEva Vanessa Schrezenmeier
Eva Vanessa Schrezenmeier
HRHector Rincon-Arevalo
Hector Rincon-Arevalo
AJAnnika Jens
Annika Jens
ASAna-Luisa Stefanski
Ana-Luisa Stefanski
CHCharlotte Hammett
Charlotte Hammett
KBKlemens Budde
Klemens Budde
Transplant recipients exhibit an impaired protective immunity after SARS-CoV-2 vaccination, potentially caused by mycophenolate (MPA) immunosuppression. Recent data from patients with autoimmune disorders suggest that temporary MPA hold might greatly improve booster vaccination outcomes. We applied a fourth dose of SARS-CoV-2 vaccine to 29 kidney transplant recipients during a temporary (5 weeks) MPA/azathioprine hold, who had not mounted a humoral immune response to previous vaccinations. Seroconversion until day 32 after vaccination was observed in 76% of patients, associated with acquisition of virus-neutralizing capacity. Interestingly, 21/25 (84%) calcineurin inhibitor–treated patients responded, but only 1/4 belatacept-treated patients responded. In line with humoral responses, counts and relative frequencies of spike receptor binding domain–specific (RBD-specific) B cells were markedly increased on day 7 after vaccination, with an increase in RBD-specific CD27 ++ CD38 + plasmablasts. Whereas overall proportions of spike-reactive CD4 + T cells remained unaltered after the fourth dose, frequencies were positively correlated with specific IgG levels. Importantly, antigen-specific proliferating Ki67 + and in vivo–activated programmed cell death 1–positive T cells significantly increased after revaccination during MPA hold, whereas cytokine production and memory differentiation remained unaffected. In summary, antimetabolite hold augmented all arms of immunity during booster vaccination. These data suggest further studies of antimetabolite hold in kidney transplant recipients.

10 April 2025 in Transplantation Direct
Verified
Journal Article
Open access
AAAylin Akifova
Aylin Akifova
KBKlemens Budde
Klemens Budde
MCMira Choi
Mira Choi
KAKerstin Amann
Kerstin Amann
MBMaike Julia Büttner-Herold
Maike Julia Büttner-Herold
BOBilgin Osmanodja
Bilgin Osmanodja
Background. Donor-derived cell-free DNA (dd-cfDNA) is an emerging biomarker of kidney allograft injury, mainly investigated in the context of rejection. However, the dd-cfDNA dynamics in other graft pathologies merit further investigation. Methods. In this single-center observational study, we prospectively collected dd-cfDNA at indication biopsies. To evaluate the association between dd-cfDNA and different histological patterns, we correlated absolute and relative dd-cfDNA (thresholds of 50 copies/mL and 0.5%, respectively) with the Banff 2022 lesion scores and the assigned diagnoses. Results. We examined 151 dd-cfDNA paired biopsies in 131 kidney transplant recipients and found significantly higher absolute dd-cfDNA levels in antibody-mediated rejection (n, median, IQR: 45, 63 copies/mL, 42–89), microvascular inflammation (MVI) without donor-specific antibodies or C4d-deposition (6, 102 copies/mL, 61–134), mixed rejection (8, 140 copies/mL, 77–171), and BK virus–associated nephropathy (6, 213 copies/mL, 83–298) compared with glomerulonephritis (20, 12 copies/mL, 8–18), calcineurin toxicity (19, 10 copies/mL, 7–16), interstitial fibrosis/tubular atrophy (12, 10 copies/mL, 9–16) and normal histology (6, 9 copies/mL, 7–16). In the multivariable analysis, absolute and relative dd-cfDNA correlated with the peritubular capillaritis (ptc), glomerulitis (g), and tubulitis (t) scores. In the receiver operating characteristic analysis, absolute dd-cfDNA showed best discrimination for MVI of any cause (area under the curve [AUC] 0.88, sensitivity 0.71, specificity 0.86, positive predictive value [PPV] 0.76, negative predictive value [NPV] 0.82), followed by antibody-mediated rejection including mixed rejection (AUC 0.85, sensitivity 0.72, specificity 0.83, PPV 0.69, NPV 0.84), and overall rejection (AUC 0.83, sensitivity 0.66, specificity 0.85, PPV 0.76, NPV 0.77). T cell–mediated rejection was only detectable by dd-cfDNA when associated with vascular lesions. Conclusions. Altogether, we conclude that dd-cfDNA-release is not limited to rejection-related injury phenotypes and is mainly driven by MVI in kidney allografts. Export

22 March 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BOBilgin Osmanodja
Bilgin Osmanodja
AAAylin Akifova
Aylin Akifova
MOMichael Oellerich
Michael Oellerich
JBJulia Beck
Julia Beck
KBKirsten Bornemann-Kolatzki
Kirsten Bornemann-Kolatzki
KBKlemens Budde
Klemens Budde
Donor-derived cell-free DNA (dd-cfDNA) is used as a biomarker for detection of antibody-mediated rejection (ABMR) and other forms of graft injury. Another potential indication is guidance of immunosuppressive therapy when no therapeutic drug monitoring is available. In such situations, detection of patients with overt or subclinical graft injury is important to personalize immunosuppression. We prospectively measured dd-cfDNA in 22 kidney transplant recipients (KTR) over a period of 6 months after conversion to belatacept for clinical indication and assessed routine clinical parameters. Patient and graft survival was 100% after 6 months, and eGFR remained stable (28.7 vs. 31.1 mL/min/1.73 m2, p = 0.60). Out of 22 patients, 2 (9%) developed biopsy-proven rejection—one episode of low-grade TCMR IA and one episode of caABMR. While both episodes were detected by increase in creatinine, the caABMR episode led to increase in absolute dd-cfDNA (168 copies/mL) above the cut-off of 50 copies/mL, while the TCMR episode did show slightly increased relative dd-cfDNA (0.85%) despite normal absolute dd-cfDNA (22 copies/mL). Dd-cfDNA did not differ before and after conversion in a subgroup of 12 KTR with previous calcineurin inhibitor therapy and no rejection (12.5 vs. 25.3 copies/mL, p = 0.34). In this subgroup, 3/12 (25%) patients showed increase of absolute dd-cfDNA above the prespecified cut-off (50 copies/mL) despite improving eGFR. Increase in dd-cfDNA after conversion to belatacept is common and could point towards subclinical allograft injury. To detect subclinical TCMR changes without vascular lesions, additional biomarkers or urinary dd-cfDNA should complement plasma dd-cfDNA. Resolving CNI toxicity is unlikely to be detected by decreased dd-cfDNA levels. In summary, the sole determination of dd-cfDNA has limited utility in the guidance of patients after late conversion to belatacept. Further studies should focus on patients undergoing early conversion and include protocol biopsies at least for patients with increased dd-cfDNA.

10 June 2026 in American Journal of Transplantation
Verified
Journal Article
Open access
Louise BenningLouise Benning
Louise Benning
AAAylin Akifova
Aylin Akifova
MOMichael Oellerich
Michael Oellerich
BOBilgin Osmanodja
Bilgin Osmanodja
CMChristian Morath
Christian Morath
KBKlemens Budde
Klemens Budde
Donor-derived cell-free DNA (dd-cfDNA) is a widely used biomarker in kidney transplantation, reported mainly as either percentage of total cfDNA or copies/mL. We hypothesized that combining both metrics into a continuous composite score would reduce false classifications thus improving the accuracy of rejection diagnosis. We analyzed 443 dd-cfDNA measurements in 361 patients from five independent kidney transplant cohorts with both percentage and copies/mL. A random discovery set of 25 biopsy-proven rejections and 26 non-rejections was used to derive a composite score (CM-Score), integrating dd-cfDNA (%) and copies/mL. Diagnostic performance was validated in 81 rejections and 282 non-rejections and compared to 11 published cohorts. For all evaluations, CM-Score was better than dd-cfDNA in copies/mL, which was better than dd-cfDNA in percent. The CM-Score retained a high NPV of 91% (89-93%), while significantly improving PPV to 81% (72-89%; P<0.0001, prevalence: 25%), compared to published values (weighted average NPV: 90% (89-92%); PPV: 54% (52-55%), N=6,536). Decision curve analysis yielded a significantly higher net benefit for the CM-Score (P<0.003). The dd-cfDNA CM-Score is a robust and clinically meaningful tool improving diagnostic accuracy for ruling-out and ruling-in rejection using dd-cfDNA as stand-alone metric with high potential to improve decision-making in kidney transplantation.

30 November 2023 in Transfusionsmedizin
Verified
Journal Article
Closed access
PDF file
BOBilgin Osmanodja
Bilgin Osmanodja
AAAylin Akifova
Aylin Akifova
KBKlemens Budde
Klemens Budde
JBJulia Beck
Julia Beck
KBKirsten Bornemann-Kolatzki
Kirsten Bornemann-Kolatzki
MOMichael Oellerich
Michael Oellerich
Eine antikörpervermittelte Abstoßung (antibody-mediated rejection, ABMR) ist die häufigste immunologische Ursache für einen späten Transplantatverlust. Mit der zellfreien Transplantat-DNA (donor-derived cell-free DNA, dd-cfDNA) steht ein neuer schädigungsspezifischer Transplantat-Biomarker zur Verfügung, welcher eine höhere Sensitivität und Spezifität für die Diagnose einer ABMR aufweist als Routine-Biomarker wie Kreatinin und Albuminurie. Wir beschreiben den Fall eines 49-jährigen Patienten nach Nierentransplantation, bei dem wir mittels dd-cfDNA frühzeitig die Diagnose einer ABMR gestellt und anschließend das Therapieansprechen überwacht haben. Der Patient hatte bereits früh nach der Transplantation ein Kaposi-Sarkom als Komplikation der Immunsuppression entwickelt, und wurde deshalb nach 5 Monaten von einer Standardimmunsuppression (Tacrolimus, Mycophenolatmofetil, Methylprednisolon) auf eine duale Immunsuppression mit Sirolimus und Methylprednisolon umgestellt. Hierunter entwickelte der Patient ca. 1,5 Jahre nach Transplantation donorspezifische Antikörper. Zwei Jahre nach Transplantation erfolgte die quantitative Messung von zellfreier Transplantat-DNA im Plasma. Da die Werte wiederholt über dem Cutoff von 50 Kopien/mL lagen, erfolgte die Nierentransplantatbiopsie und sicherte die Diagnose einer aktiven ABMR nach der Banff-Klassifikation 2019. Nach Ausschluss eines Rezidivs des Kaposi-Sarkoms erfolgte die Therapieeinleitung mittels Plasmapherese und intravenösen Immunglobulinen, sowie die Ergänzung der immunsuppressiven Therapie um Mycophenolatmofetil. Hierunter konnte mittelfristig eine Reduktion der dd-cfDNA unter den Cutoff, sowie eine Stabilisierung der Nierenfunktionsparameter (Kreatinin und Albuminurie) erreicht werden. Antibody-mediated rejection (ABMR) is the most common immunological cause of late allograft loss. Donor-derived cell-free DNA (dd-cfDNA) provides a new injury-specific allograft biomarker, which has higher sensitivity and specificity for the diagnosis of ABMR than routine biomarkers such as creatinine and albuminuria. We describe the case of a 49-year-old patient after kidney transplantation, where we used dd-cfDNA to establish an early diagnosis of ABMR and to monitor treatment response subsequently. The patient had developed Kaposi's sarcoma early after transplantation as a complication of immunosuppression, and was therefore switched from standard immunosuppression (tacrolimus, mycophenolate mofetil, methylprednisolone) to dual immunosuppression with sirolimus and methylprednisolone after 5 months. Consequently, the patient developed donor-specific antibodies approximately 1.5 years after transplantation. Two years after transplantation, dd-cfDNA concentration was measured in plasma. Because the levels were repeatedly above the cutoff of 50 copies/ml, kidney allograft biopsy was performed and established the diagnosis of active ABMR according to Banff classification 2019. After exclusion of recurrence of Kaposi's sarcoma, plasmapheresis and intravenous immunoglobulins were initiated, and mycophenolate mofetil was added again to the maintenance immunosuppression. This resulted in a reduction of dd-cfDNA below the cutoff and stabilization of renal function parameters (creatinine and albuminuria). Article published online: 30 November 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart, Germany